Beyond Air® to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
02. November 2021 08:00 ET
|
Beyond Air™
GARDEN CITY, N.Y., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air® Schedules Second Fiscal Quarter 2022 Financial Results Conference Call and Webcast
25. Oktober 2021 08:00 ET
|
Beyond Air™
GARDEN CITY, N.Y., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air® Reports Positive Interim Results for LungFit® GO Pilot Study Using High Concentration Inhaled Nitric Oxide Self-Administered, At-Home for Nontuberculous Mycobacterial Lung Disease
20. Oktober 2021 08:00 ET
|
Beyond Air™
Interim results show that 250 parts per million (ppm) nitric oxide (NO) was well-tolerated with no study discontinuations or treatment-related serious adverse events observed At the time of data...
Beyond Air® Provides Global Regulatory Update for LungFit® PH
21. September 2021 16:30 ET
|
Beyond Air™
FDA inspection of facilities is ongoing; US commercial launch remains on track for 4Q CY2021, pending FDA approval Stage 1 Assessment Audit in the CE Mark process is complete; expect to receive CE...
Beyond Air® to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
14. September 2021 07:30 ET
|
Beyond Air™
GARDEN CITY, N.Y., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air® Announces CFO Transition
20. August 2021 16:15 ET
|
Beyond Air™
GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2022
10. August 2021 16:05 ET
|
Beyond Air™
U.S. FDA reviewing premarket approval (PMA) submission for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); On track for commercial launch in the fourth quarter of...
Beyond Air® Schedules First Fiscal Quarter 2022 Financial Results Conference Call and Webcast
20. Juli 2021 07:30 ET
|
Beyond Air™
GARDEN CITY, N.Y., July 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in July 2021
08. Juli 2021 16:14 ET
|
Beyond Air™
GARDEN CITY, N.Y., July 08, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021
10. Juni 2021 16:05 ET
|
Beyond Air™
Submitted first premarket approval (PMA) application in the Company’s history to FDA for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Company preparing for commercial...